Angiotensin receptor blockers (ARBs) vs placebo
Number of participants reporting an adverse event · adults with early (stage 1 to 3) non‐diabetic CKD
It is very uncertain whether angiotensin receptor blockers changes adverse events (number reporting an adverse event) compared with placebo (very low certainty).
1 finding from 1 review
- Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3)… 2023 · Cochrane Headline outcomes onlyRR 19.34 [1.14, 328.3]1 study · 226 participantsVery low